TRIM-ing Ligand Dependence in Castration-Resistant Prostate Cancer.

Patel, Lalit R; Barton, Michelle C

Patel, Lalit R; Barton, Michelle C.

Afiliação

Patel LR; Department of Epigenetics and Molecular Carcinogenesis, Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA.
Barton MC; Department of Epigenetics and Molecular Carcinogenesis, Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA. Electronic address: mbarton@mdanderson.org.

Cancer Cell ; 29(6): 776-778, 2016 06 13.

Article em En | MEDLINE | ID: mdl-27300431

ABSTRACT

ABSTRACT

Prostate cancer is lethal when tumors evolve to activate androgen receptor signaling, which circumvents ligand-deprivation therapy. In this issue of Cancer Cell, Groner et al. show that histone reader and transcription co-regulator TRIM24 occupies a central role in this evolution, nominating inhibitors of TRIM24's bromodomain as a new therapeutic avenue.

Assuntos

Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico; Receptores Androgênicos/genética; Humanos; Ligantes; Masculino; Neoplasias da Próstata/tratamento farmacológico; Transdução de Sinais; Transcrição Gênica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores Androgênicos / Neoplasias de Próstata Resistentes à Castração Limite: Humans / Male Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google